Trans-national Access (TA) ensures free-of-charge access to the services and expertise of the EurOPDX Research Infrastructure. This opportunity is open to academic and industry researchers from across Europe and worldwide. As part of the H2020 EDIReX grant, three TA calls will be launched between 2018 and 2020.
Second Call for trans-national access opens in September 2019!
In addition to sample and deposit access types, a new test access will be offered in the second call - more details of this new access type will be published shortly.
From the 2nd call, access will be possible through three different access types
Shipment of frozen PDX tumour samples to selected academic laboratories
Each user of the infrastructure will receive viable tissue aliquots from the PDX models she/he would have selected for their particular features in the public EurOPDX Data Portal. Prior to shipment, all PDX models will have been expanded, biobanked, and quality controlled (histology, identity check, health monitoring) in one of the six nodes according to the standards agreed within the EurOPDX RI. Each model will be accompanied by a “PDX passport”, a factsheet developed by the EurOPDX RI to contain all main features of a given PDX model, such as histology, strain, growth characteristics. Access also includes support/consulting to the users after shipment of models, for the handling of samples, design of in vivo studies etc…
The access to the SAMPLE service is free of charge, and available for the performance of non-commercial research activities only. However, the shipment cost of frozen vials to the user’s laboratory must be borne by the user.
Deposition of PDX models into the repository and infrastructure biobank
The user’s PDX models selected for deposition into the EurOPDX RI biobank will be health checked according to our Health monitoring SOP, and if cleared expanded, biobanked, and quality controlled (histology, identity check, health monitoring) in one of the six nodes according to the standards agreed within the EurOPDX RI.
In parallel to this biobanking process, PDXs data (metadata, as well as molecular and/or pharmacological data if available) will be collected to be included in the public EurOPDX Data Portal. Each model will be accompanied by a “PDX passport”, a factsheet developed by the EurOPDX RI to contain all main features of a given PDX model, such as histology, strain, growth characteristics.
Once deposited into the EurOPDX RI and Data Portal, users’ models will be made available to the scientific community for TA, through the SAMPLE service described above, or at minima on a collaborative basis if properly justified by the owner of the models. A grace period is possible to allow for proper publication and/or protection of a model.
The access to the DEPOSIT service is free of charge. However, the shipment cost of frozen vials from the user’s laboratory to the designated infrastructure node must be borne by the user.
Performance of in vivo studies on selected PDX models at one of our 6 infrastructure nodes.
The user will select PDX model(s) for their particular features in the public EurOPDX Data Portal. The chosen model(s) will be expanded in one of our infrastructure node facilities. The user will then supply their drug of interest. The infrastructure node will then perform an in vivo experiment according to the users needs. The user will receive an experimental report detailing the results and quality control measures undertaken.
The access to the TEST service is free of charge. However, the shipment cost of the drug(s) of interest from the user’s laboratory to the designated infrastructure node must be borne by the user.
The TEST access type is open to both Academic and Industry researcher
Trans-national Access to the EurOPDX Research Infrastructure is free of charge for selected users, costs being covered by the EurOPDX Research Infrastructure grant. However, the shipment cost of the samples must be borne by the applicants.
Eligible proposals will be selected by a mixed panel of partners of the EurOPDX Research Infrastructure project (for feasibility under the grant) and an independent committee of external evaluators.
We established a Committee of TA Evaluators (TA-CE), as a mixed panel consisting of external experts in the field of molecular, translational, preclinical and clinical oncology, and experts from the EurOPDX Consortium. Evaluators are covering a wide range of cancer types and expertise in the field. While EurOPDX evaluators will mainly focus on eligibility and feasibility of the proposals under the grant, two external and independent evaluators will review each submitted project proposals with respect to the following criteria:
- Scientific excellence (originality and scientific quality)
- Expected impact (interest to the wider scientific community and societal needs)
Whilst also considering aspects such as:
- The prioritisation of new users and users who work in countries where no such Research Infrastructures exists
- Gender balance
- Career stage of applicant
All applications will be handled with strict confidentiality.
A scoring system is being established, and will allow objective selection of successful applications.
The list of TA-CE evaluators will be made available on our project website by the end of 2018.
Results of the evaluation will be sent by email.
Available models for “Sample” and “Test” access
720 models from 3 EurOPDX Research Infrastructure partners have been made available for transnational access*.
To browse our available models, use the newly designed EurOPDX Data Portal*new models are being continually added, so please check back regularly
The Guide for Applicants: Download
The form to apply for Sample Ta unit(s): Download
The form to apply for Deposit Ta unit(s): Download
Submit your completed application form to firstname.lastname@example.org
Nodes providing access:
TA will be provided by a distributed infrastructure composed of six independent nodes, which are state-of-the-art laboratories or platforms performing research using PDX models:
- University of Torino, Department of Oncology at Candiolo Cancer Institute IRCCS, Xenopatients' Platform for Experimental Oncology (Candiolo, Italy)
- Katholieke Universiteit Leuven, Trace PDX platform (Leuven, Belgium)
- The University of Cambridge, Cancer Research UK Cambridge Institute, Carlos Caldas laboratory (Cambridge, UK)
- Institut Curie, Laboratory of Preclinical Investigation (Paris, France)
- Vall d’Hebron Institute of Oncology, CELLEX building (Barcelona, Spain)
- Netherlands Cancer Institute, Preclinical Intervention Unit of the Mouse Clinic for Cancer and Ageing (Amsterdam, the Netherlands)
For any questions regarding the EurOPDX Research Infrastructure Trans-national access programme, please contact our helpdesk at: email@example.com
The 2nd and 3rd calls for access will open in September 2019 and Spring 2020 respectively. Fill in your details above to be informed of these calls closer to the time.
From the 2nd call “Test” access will also be available - performance of in vivo preclinical experiments on PDXs engrafted in immunocompromised mice”